Glutamine is subtle to undetectable acutely. Most users report nothing. The dopamine.club community-data mirrors this: across 251 reports, top "effects" are recovery (29), energy (26), focus (25), gut-improvement (22), sleep-quality (19) — small counts relative to the base, and "focus" + "energy" + "muscle-growth" are likely placebo-amplified given mechanistic implausibility at 5 g with splanchnic first-pass. Mechanistically defensible signals (gut-improvement, sleep-quality) also show up in the small RCT base.

Honest framing: take glutamine for what you don't notice. Slightly fewer minor GI complaints during high-volume training. Slightly fewer sniffles during fight-camp intensification. Slightly less post-session depletion. Week-1 acute changes are almost certainly placebo.

At higher doses (10–15 g) some users report vague gut comfort or reduced bloat, sometimes slight calming (GABA-precursor pathway mechanistically downstream, operationally weak at oral doses). No euphoria, no cognitive sharpening, no acute mood change. This is gut/immune insurance, not stimulation.

Post-exhaustion ammonia-clearance signal is real but only detectable in laboratory protocols with reaction-time tests after near-VO2max efforts. MMA training rarely pushes into that ammonia-spike range — exception: terminal weight-cut hours where carb depletion + dehydration + sodium loading + sauna stacks ammonia symptomatically. Plausible insurance there, not first-line.

Community texture: repeat-user trend (n=10, median 12 days, 2 more-positive vs 1 more-negative) — most chronic users settle into "neutral" within ~2 weeks, consistent with the "insurance, not stimulation" framing. Discord traffic is skeptical of the more dramatic claims.

• Tolerance buildup: none documented. Mechanism is substrate-replacement / fuel-provision, not receptor-mediated. The body simply uses what's available; excess is metabolized normally via existing enzyme systems (glutaminase, glutamine synthetase, GS-driven anaplerotic feed). No receptor downregulation, no acute desensitization, no withdrawal phenomenon. This is one of the cleanest "no-tolerance" pharmacological profiles in the supplement space.
• Recommended cycle: none needed for daily 5 g use. Block-cycling (only during peak training, fight camps, or weight cuts) is reasonable from a cost-efficacy standpoint, not pharmacological necessity. Two equally defensible patterns:
  • Continuous daily 5 g/day: Year-round insurance, simple compliance, ~$5–10/mo.
  • Block-cycled: Off during base/maintenance; 5–10 g/day during fight-camp intensification; 15–21 g/day (Lu-style) for 3 weeks during peak overreaching or weight cuts.
• Reset protocol: N/A. No washout requirement, no glutamine-tolerance to clear.
• Stopping: No discontinuation syndrome. Endogenous synthesis returns to baseline within hours; plasma glutamine pool restored within days from normal dietary intake.

Synergistic with

• n-acetyl-cysteine (NAC): Both contribute to glutathione synthesis (NAC = cysteine donor; glutamine = glutamate donor; glycine = the third amino acid in GSH). NAC is rate-limiting; glutamine helps marginally. Reasonable mitochondrial / antioxidant pair during high training stress, especially when paired with hard training and heat/altitude exposure.
• glycine: Both are gut-barrier supportive amino acids and both feed into GSH synthesis. Glycine has additional sleep, collagen, and methylation roles. Stack-safe; common in "gut healing" protocols. Both also intracellular osmolytes — additive cell-volume effects unstudied but mechanistically plausible.
• taurine: Both osmolyte / cell-volume / mitochondrial-support amino acids. Both daily-safe. Stack-safe. Dylan's V4 stack already includes taurine; glutamine slots in cleanly.
• alcar (acetyl-L-carnitine): Mitochondrial energy support; ALCAR provides acetyl + carnitine for fatty-acid oxidation; glutamine provides anaplerotic alpha-ketoglutarate to refill TCA intermediates. Theoretical synergy for sustained training output; light direct empirical data but mechanistically clean.
• Creatine: Both are intracellular osmolytes; both are cheap, daily-safe, well-characterized. The community-data block shows creatine as the most-combined-with substance (74 mentions), reflecting the bodybuilding-stack legacy. Synergy mostly additive, not multiplicative.
• Probiotics, zinc carnosine, deglycyrrhizinated licorice (DGL), marshmallow root, slippery elm: Standard "gut healing" stack. Glutamine is the foundational amino acid in this protocol; the others are complementary mucosal protectants.
• EAA / BCAA / whey protein: Glutamine is technically not in BCAA (leucine, isoleucine, valine), but is included in some "fermented EAA" formulas. No antagonism. Stack-safe. If Dylan is hitting 1.6–2.2 g/kg/day protein (almost certainly true for MMA), dietary glutamine intake is already in the 3–6 g range — supplemental 5 g doubles the daily exposure without exceeding safe-intake by any reasonable measure.
• Curcumin, DHA, vitamin C: All anti-inflammatory adjuncts; stack-safe; no antagonism.

Avoid stacking with

• Cancer chemotherapy (without oncologist guidance): Glutamine is used clinically for chemo-mucositis with mortality benefit in some trials. The simultaneous theoretical concern about feeding glutamine-addicted tumors means oncologist-led dosing only. Healthy users with cancer family history: no contraindication at standard supplementation doses.
• Lithium, MAOIs, high-dose stimulants: No documented direct interaction, but in seizure-prone or psychiatrically unstable individuals the glutamate-precursor mechanism is a theoretical concern. Conservative recommendation: avoid in those populations.
• Active hepatic encephalopathy / advanced cirrhosis: Avoid — ammonia load via impaired urea cycle.
• Lactulose (used to lower ammonia in cirrhosis): Theoretical pharmacological antagonism. Avoid co-administration.

Neutral / safe co-administration

• All canonical Dylan stack components: NAC, citicoline, magnesium glycinate + threonate, DHA, PS, curcumin, rhodiola, L-theanine, glycine, D3+K2, beta-alanine, vitamin C, creatine, taurine.
• All V5 planned stack additions: modafinil, bromantane, Adamax/Semax, ALCAR, apigenin, astaxanthin, L-tryptophan.
• Whey, casein, EAA, BCAA, creatine: all standard sport stacks; no interaction.
• Coffee, caffeine, L-theanine: stack-safe.
• Modafinil + glutamine combo: No documented interaction; theoretically clean since modafinil works through DAT/orexin/histamine and glutamine through entirely different pathways. The community-data shows caffeine as the 6th most-combined-with substance (49 mentions) — same kinetic profile.

• CYP enzymes: Glutamine is not a CYP inducer or inhibitor. No interactions with modafinil (CYP3A4 inducer), bupropion (CYP2B6), or other CYP-metabolized stack drugs. Metabolized by dedicated AA-pathway enzymes outside CYP.
• Lactulose (hepatic encephalopathy): Theoretical antagonism — lactulose traps NH4+, glutamine generates ammonia. Avoid co-administration in cirrhotic patients.
• Anticonvulsants (lamotrigine, valproate, levetiracetam, topiramate, carbamazepine): No documented interaction. Theoretical concern about marginal glutamate elevation in seizure-prone individuals; clinical relevance unestablished at supplemental doses.
• Contraceptives: No interaction. No CYP3A4 induction.
• Cancer therapeutics: Variable. Used clinically alongside chemo for mucositis benefit; avoided in advanced-tumor protocols where glutaminolysis is being therapeutically inhibited (CB-839). Oncologist guidance required.
• Insulin / oral hypoglycemics: Gluconeogenic substrate with mild glucose-modulating effect; clinically negligible at supplemental doses.
• MAOIs, antipsychotics, levodopa, antibiotics: No documented interactions.
• NSAIDs: No pharmacological interaction; mechanistically beneficial co-administration in patients on chronic NSAIDs (counters NSAID-induced gut permeability).

Glutamine metabolism involves glutaminase (GLS, GLS2), glutamine synthetase (GLUL), and transporters SLC1A5 (ASCT2), SLC7A11 (xCT), SLC38A2 (SNAT2). Variants in each have been studied primarily in cancer biology, not supplementation pharmacogenomics.

• GLS / GLS2: Polymorphisms theoretically alter glutamate generation rate; almost all literature is tumor-context. No clinical recommendations for genotype-guided supplementation dosing.
• GLUL (glutamine synthetase): Homozygous LOF variants cause rare neonatal glutamine deficiency syndromes; adult heterozygotes have negligible clinical relevance for supplementation.
• SLC1A5 / ASCT2: Tumor glutamine import transporter; clinical relevance for healthy-adult supplementation undocumented.
• SLC7A11 (xCT), GAD1/GAD2: Affect cystine/glutamate antiport (GSH pathway) and GABA synthesis. Theoretically relevant; practically moot at oral doses given splanchnic first-pass.
• 23andMe relevance for Dylan: Once results land (~June 5–15, 2026), no panel variants rise to actionable-status for glutamine dosing. Stack-relevant genes (MTHFR, COMT, APOE) are not glutamine-specific.

Form considerations: Powder vs capsules — powder is ~3–5× cheaper per gram and dissolves cleanly in water at body temp. Capsules are convenient but require 5× more pills at 5 g/day (5 caps of 1 g). Liquid pre-mixed formulas should be avoided because of the Discord-cited in-solution ammonia degradation problem (glutamine is unstable in aqueous solution at room temp >24h).

Free-form vs dipeptide: Clinical critical-illness trials often use alanyl-glutamine or glycyl-glutamine dipeptides (Dipeptiven, etc.) because dipeptides survive parenteral storage better. For oral use, free L-glutamine is equivalent in absorption + activity; the dipeptide cost premium is not justified.

Recommended for Dylan: BulkSupplements powder if going bulk-cheap, or NOW Foods caps via iHerb (already in V4 supplier flow). Cost is trivially small (~$5–10/mo at 5 g/day powder; ~$15–25/mo at 5 g/day caps). If escalating to Lu-protocol 21 g/day for fight camp: ~$25–40/mo at that dose.

• Baseline: None strictly required at 5 g/day. Gut-targeting: zonulin (serum or stool), GI-MAP, lactulose/mannitol (research labs), 2-week GI symptom log. Immune-targeting: URTI episode count last 6 months + average illness duration. Training-load: TRIMP or HRV trend.
• During use (5 g/day daily):
  • URTI frequency self-report — primary endpoint.
  • GI symptom log (daily 1–10: bloating, gas, stool quality, post-meal comfort).
  • HRV / RHR via wearable (Dylan has ring + watch data) — autonomic recovery proxy.
  • Subjective recovery + sleep quality (daily 1–10).
  • CRP, IL-6 at 8–12 weeks if high training load + bloodwork access (Dylan pipeline lands ~June 2026).
• During use (Lu protocol, 21 g/day × 3 weeks):
  • Salivary IgA + nitric oxide — Lu 2024 primary endpoints (specialty labs, $50–150/kit).
  • Salivary cortisol AM/PM + salivary testosterone — for T/C ratio replication.
  • URTI frequency + duration as primary outcome.
• Post-cycle: N/A (not cycled). For block-cycle: re-check gut + URTI frequency on/off blocks.
• Plasma glutamine (research-grade): LabCorp/Quest amino acid panel ($100–300). Low (<450 µmol/L) is a reasonably reliable overtraining biomarker in endurance athletes; weaker validation in MMA. Worth one baseline reference; not worth repeating absent clinical reason.
• Gut permeability markers (specialty): Zonulin (serum/stool), lactulose/mannitol, occludin antibodies — not routine at 5 g/day; useful in gut-symptom workups.